E L Knight
Overview
Explore the profile of E L Knight including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
353
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glynn R, Knight E, Levin R, Avorn J
Epidemiology
. 2001 Oct;
12(6):682-9.
PMID: 11679797
Medication use patterns provide popular surrogate measures of disease, yet selective under-use of drugs by elderly patients with potentially unmeasured comorbidity may lead to artifactual "protective" associations between use of...
2.
Knight E, Bohn R, Wang P, Glynn R, Mogun H, Avorn J
Hypertension
. 2001 Oct;
38(4):809-14.
PMID: 11641291
Hypertension remains poorly controlled in the United States. Improvement of its management will require an understanding of the patient characteristics and treatment factors associated with uncontrolled hypertension. We studied antihypertensive...
3.
Knight E, Avorn J
Ann Intern Med
. 2001 Oct;
135(8 Pt 2):703-10.
PMID: 11601953
No abstract available.
4.
Yanos P, Primavera L, Knight E
Psychiatr Serv
. 2001 Mar;
52(4):493-500.
PMID: 11274496
Objective: This study examined the relationship between participation in consumer-run services and recovery of social functioning among persons diagnosed as having serious mental illness. It also assessed the role of...
5.
Ganz D, Glynn R, Mogun H, Knight E, Bohn R, Avorn J
J Gen Intern Med
. 2000 Dec;
15(11):776-81.
PMID: 11119169
Objective: Guidelines for oral anticoagulation after deep venous thrombosis (DVT) or pulmonary embolism (PE) have recommended that patients be anticoagulated for at least 3 months after hospital discharge. We sought...
6.
Knight E, Warner A, Maxwell A, Prigent S
Oncogene
. 2000 Dec;
19(47):5398-405.
PMID: 11103941
Despite much interest in vascular endothelial growth factor (VEGF) and its receptors (VEGFRs -1 and -2), VEGF-induced signalling cascades remain incompletely defined. Attempts to assign individual responses to a particular...
7.
Knight E, Glynn R, Levin R, Ganz D, Avorn J
J Gen Intern Med
. 2000 Nov;
15(10):702-9.
PMID: 11089713
Objective: Throughout the 1990s, the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure recommended initial antihypertensive therapy with a thiazide diuretic or a beta-blocker based on...
8.
Warner A, Knight E, Feramisco J, Prigent S
Biochem J
. 2000 Apr;
347(Pt 2):501-9.
PMID: 10749680
Despite much progress in recent years, the precise signalling events triggered by the vascular-endothelial-growth-factor (VEGF) receptors, fms-like tyrosine kinase (Flt1) and kinase insert domain-containing receptor (KDR), are incompletely defined. Results...
9.
10.
Knight E, Glynn R, McIntyre K, Mogun H, Avorn J
Am Heart J
. 1999 Oct;
138(5 Pt 1):849-55.
PMID: 10539815
Background: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function. Little information is available to predict which...